Valuation: PREDILIFE

Market Cap 51.3L 58.7L 47.34L 43.63L 82.24L 57Cr 84.07L 5.66Cr 2.23Cr 28Cr 2.2Cr 2.16Cr 95Cr P/E 2024
-3.18x
P/E 2025 -3.01x
Enterprise Value 99.08L 1.13Cr 91.43L 84.27L 1.59Cr 109.18Cr 1.62Cr 11Cr 4.3Cr 53Cr 4.26Cr 4.16Cr 184.08Cr EV / Sales 2024
34.5x
EV / Sales 2025 19.3x
Free-Float
48.75%
Yield 2024 *
-
Yield 2025 -
1 day-13.33%
1 week-27.98%
Current month-43.48%
1 month-46.28%
3 months-58.60%
6 months-60.73%
Current year-56.81%
1 week 1.3
Extreme 1.3
1.8
1 month 1.3
Extreme 1.3
2.57
Current year 1.3
Extreme 1.3
4
1 year 1.3
Extreme 1.3
4
3 years 1.3
Extreme 1.3
24
5 years 1.3
Extreme 1.3
24
10 years 1.3
Extreme 1.3
24
Manager TitleAgeSince
Chief Executive Officer 56 01/01/2004
Chief Tech/Sci/R&D Officer - 01/01/2007
General Counsel - 01/01/2016
Director TitleAgeSince
Director/Board Member 46 01/01/2018
Chairman 56 01/01/2004
Director/Board Member 58 01/01/2018
Date Insider Type Main position Quantity % Market Cap.
27/07/23 Buy

Chief Executive Officer

1,200 0.0328%
23/03/22 Sell

Chief Executive Officer

3,000 0.0820%
09/03/22 Buy

Chief Executive Officer

2,000 0.0546%
Change 5-day change 1-year change 3-year change Capi.($)
-13.33%-27.98%-59.75%-77.78% 58.7L
-0.15%+3.79%+151.51%+98.56% 471.81Cr
+3.71%+8.83%+120.60%+201.98% 366.82Cr
+7.30%+18.20%+124.22%-38.65% 223.25Cr
-1.51%+39.35%+233.45%+285.35% 205.24Cr
-5.50%-0.75%-29.67%-37.76% 203.53Cr
+2.12%+18.88%+197.94%-41.99% 106.79Cr
-2.39%-1.55%-10.78%+35.95% 87Cr
-4.16%+6.17%-34.21%-11.74% 51Cr
-3.06%-3.18%-3.97% - 48Cr
Average -1.70%+6.32%+68.93%+45.99% 176.44Cr
Weighted average by Cap. +0.65%+10.75%+115.37%+93.70%

Financials

2024 2025
Net sales 5L 6L 5L 4L 8L 5.43Cr 8L 54.4L 21.4L 2.66Cr 21.19L 20.73L 9.16Cr 8L 10L 8L 7L 13.4L 9.21Cr 13.7L 92.19L 36.26L 4.51Cr 35.92L 35.13L 16Cr
Net income -42.65L -48.8L -39.35L -36.27L -68.37L -47Cr -69.89L -4.7Cr -1.85Cr -23Cr -1.83Cr -1.79Cr -79Cr -39.34L -45.02L -36.31L -33.47L -63.08L -43Cr -64.48L -4.34Cr -1.71Cr -21Cr -1.69Cr -1.65Cr -73Cr
Net Debt 35.38L 40.49L 32.65L 30.1L 56.73L 39Cr 57.99L 3.9Cr 1.54Cr 19Cr 1.52Cr 1.49Cr 66Cr 47.78L 54.67L 44.09L 40.64L 76.59L 53Cr 78.29L 5.27Cr 2.07Cr 26Cr 2.05Cr 2.01Cr 89Cr
Logo PREDILIFE
PREDILIFE specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk®, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk® makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of over 1,000,000 American women, and over 300,000 French women. PREDILIFE also develops multi-pathology tests to screen for colon, prostate and lung cancer, melanoma and cardiovascular risks.
Employees
21
Date Price Change Volume
17/26/17 €1.300 -13.33% 1,144
16/26/16 €1.500 -16.90% 2,750
15/26/15 €1.805 0.00% 0
14/26/14 €1.805 0.00% 0
13/26/13 €1.805 0.00% 0

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALPRE Stock